Latest Market Access News

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for its suite of 27 ETFs on the ASX, updating investment strategies, fee structures, risk factors, and operational details.

Almonty Industries will delist from the Toronto Stock Exchange by July 31, 2026, focusing its trading exclusively on Nasdaq to streamline costs and align with where most activity occurs.

OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.

Galilee Energy’s Zydeco-1 well in Louisiana has intersected the Homeseeker B sand as predicted, revealing strong gas indications that were not factored into prior financial models. Drilling now advances toward the primary Tweedel Sand target, with electric logging due late July to assess commercial viability.

Lotus Resources has completed key acid plant repairs at its Kayelekera uranium mine, targeting production restart in early August 2026 and steady-state output by late year. The company also formalised a binding commitment with Mercuria for a US$30 million prepayment facility amid ongoing funding negotiations.

Lindian Resources has secured independent validation from ANSTO of a complete hydrometallurgical flowsheet for its Kangankunde monazite concentrate, achieving near-complete NdPr extraction and producing a non-radioactive mixed rare earth carbonate product ready for commercial processing.

Steadfast Group has granted a four-week extension to the exclusivity period for its non-binding $6 per share acquisition proposal from a consortium led by Amwins and Dragoneer, following their re-confirmation to proceed.

ADX Energy has increased its Austrian production by 35% following a behind pipe perforation program on two Vienna Basin wells, adding 75 barrels of oil equivalent per day. Plans for further drilling in 2027 aim to build on this momentum.

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

Spenda Limited's SPXOB securities have been suspended from trading by the ASX due to non-compliance with listing requirements. The suspension affects only this security class, leaving other Spenda securities unaffected.